Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (73585) 73585
Newsletter (13758) 13758
Publication (6372) 6372
Newspaper Article (1629) 1629
Book Review (1024) 1024
Magazine Article (629) 629
Book Chapter (236) 236
Conference Proceeding (89) 89
Dissertation (78) 78
Trade Publication Article (76) 76
Transcript (42) 42
Book / eBook (38) 38
Government Document (28) 28
Web Resource (22) 22
Reference (11) 11
Data Set (7) 7
Paper (6) 6
Streaming Video (4) 4
Journal / eJournal (2) 2
Presentation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
postmenopausal women (70105) 70105
humans (49897) 49897
female (46376) 46376
middle aged (27590) 27590
index medicus (26896) 26896
aged (21733) 21733
osteoporosis (21319) 21319
research (17827) 17827
risk factors (16511) 16511
health aspects (16018) 16018
endocrinology & metabolism (14255) 14255
adult (13653) 13653
women (13437) 13437
breast cancer (13273) 13273
menopause (12862) 12862
male (11471) 11471
estrogen (11228) 11228
cancer (10969) 10969
obstetrics & gynecology (8896) 8896
care and treatment (8699) 8699
bone density (8569) 8569
animals (8274) 8274
risk (7954) 7954
oncology (7780) 7780
hormone replacement therapy (7486) 7486
analysis (7457) 7457
aged, 80 and over (7179) 7179
bone-mineral density (6795) 6795
fractures (6757) 6757
postmenopause (6682) 6682
bones (6563) 6563
density (6483) 6483
prevention (6187) 6187
oncology, experimental (5895) 5895
reports (5489) 5489
medicine & public health (5425) 5425
medicine, general & internal (5094) 5094
physiological aspects (4864) 4864
orthopedics (4837) 4837
hormone therapy (4815) 4815
bone mineral density (4716) 4716
postmenopausal osteoporosis (4613) 4613
mineral density (4491) 4491
osteoporosis, postmenopausal - drug therapy (4445) 4445
tamoxifen (4408) 4408
estrogen replacement therapy (4387) 4387
bone density - drug effects (4318) 4318
body mass index (3970) 3970
drug therapy (3792) 3792
article (3774) 3774
medical research (3771) 3771
prospective studies (3756) 3756
treatment outcome (3684) 3684
rats (3671) 3671
therapy (3625) 3625
exercise (3620) 3620
obesity (3473) 3473
absorptiometry, photon (3449) 3449
endocrinology (3442) 3442
estradiol (3432) 3432
diagnosis (3425) 3425
rheumatology (3420) 3420
hip fracture (3381) 3381
osteoporosis, postmenopausal - prevention & control (3354) 3354
pharmacology & pharmacy (3312) 3312
cross-sectional studies (3307) 3307
randomized controlled-trial (3252) 3252
breast neoplasms - drug therapy (3249) 3249
nutrition & dietetics (3248) 3248
epidemiology (3188) 3188
medicine, experimental (3184) 3184
breast-cancer (3170) 3170
hormones (3169) 3169
risk-factors (3145) 3145
bone density - physiology (3101) 3101
ovariectomy (3088) 3088
geriatrics & gerontology (3077) 3077
age (2928) 2928
internal medicine (2902) 2902
prevalence (2879) 2879
case-control studies (2866) 2866
bone density conservation agents - therapeutic use (2861) 2861
age factors (2815) 2815
cohort studies (2763) 2763
replacement therapy (2749) 2749
womens health (2737) 2737
cardiovascular-disease (2726) 2726
diet (2720) 2720
time factors (2662) 2662
double-blind (2651) 2651
mortality (2611) 2611
men (2602) 2602
mass (2582) 2582
follow-up studies (2561) 2561
vitamin d (2560) 2560
health (2539) 2539
public, environmental & occupational health (2502) 2502
calcium (2499) 2499
surveys and questionnaires (2481) 2481
risk assessment (2474) 2474
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (24) 24
Online Resources - Online (18) 18
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
New College (Ivey) - Stacks (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
UofT at Mississauga - Stacks (2) 2
Lakeridge Health Sciences - Oshawa (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (85975) 85975
German (994) 994
French (690) 690
Spanish (533) 533
Japanese (306) 306
Polish (222) 222
Chinese (191) 191
Korean (152) 152
Portuguese (120) 120
Russian (117) 117
Turkish (113) 113
Italian (110) 110
Danish (75) 75
Czech (59) 59
Swedish (51) 51
Hungarian (45) 45
Norwegian (42) 42
Croatian (40) 40
Dutch (31) 31
Finnish (25) 25
Serbian (19) 19
Persian (18) 18
Slovak (18) 18
Bulgarian (16) 16
Slovenian (12) 12
Hebrew (8) 8
Romanian (8) 8
Lithuanian (5) 5
Malay (4) 4
Arabic (3) 3
Ukrainian (3) 3
Bosnian (1) 1
Estonian (1) 1
Georgian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Treatment of the postmenopausal woman
: basic and clinical aspects
by Lobo, Rogerio A
1994, ISBN 0781701139, xvii, 443
Estrogen Replacement Therapy | Women's Health | Osteoporosis, Postmenopausal | Hormone therapy | Complications | Menopause | physiology
Book
Details down arrow
2. Full Text Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: A consensus document of the Belgian Bone Club
by Bergmann, P and Body, J.-J and Boonen, S and Boutsen, Y and Devogelaer, J.-P and Goemaere, S and Kaufman, J.-M and Reginster, J.-Y and Gangji, V and Advisory Board Bone Markers and Members of Advisory Board on Bone Markers and Members of the Advisory Board on Bone Markers
International Journal of Clinical Practice, ISSN 1368-5031, 01/2009, Volume 63, Issue 1, pp. 19 - 26
To review the clinical value of bone turnover markers (BTM), to initiate and/or monitor anti-resorptive treatment for osteoporosis compared with bone mineral... 
MEDICINE, GENERAL & INTERNAL | ANTIFRACTURE EFFICACY | POSTMENOPAUSAL OSTEOPOROSIS | UNDERCARBOXYLATED OSTEOCALCIN | ALKALINE-PHOSPHATASE | ELDERLY-WOMEN | VERTEBRAL FRACTURE | I COLLAGEN | DEGRADATION PRODUCTS | FRACTURE INTERVENTION TRIAL | PREDICTS HIP FRACTURE | Biomarkers - metabolism | Humans | Middle Aged | Risk Factors | False Negative Reactions | Osteoporosis, Postmenopausal - urine | Evidence-Based Medicine | Osteoporosis, Postmenopausal - drug therapy | Bone Density - drug effects | Fractures, Bone - etiology | Osteoporosis, Postmenopausal - blood | Diphosphonates - therapeutic use | Female | Aged | Patient Compliance | Usage | Clinical chemistry | Phosphatases | Menopause | Practice guidelines (Medicine) | Postmenopausal women | Patient compliance | Risk factors | Osteoporosis | Diphosphonates | Collagen | Drug therapy | Public health | Fractures | Womens health | Bone density | Disease management | Health risk assessment | Evidence-based medicine | Consensus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text European guidance for the diagnosis and management of osteoporosis in postmenopausal women
by Kanis, J A and McCloskey, E V and Johansson, H and Cooper, C and Rizzoli, R and Reginster, J.-Y and IOF and ESCEO and Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) and on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF)
Osteoporosis International, ISSN 0937-941X, 1/2013, Volume 24, Issue 1, pp. 23 - 57
Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis.The International... 
Treatment of osteoporosis | FRAX | Health economics | Medicine & Public Health | Orthopedics | Gynecology | Fracture risk assessment | Rheumatology | Bone mineral density | Endocrinology | Diagnosis of osteoporosis | INCREASED CARDIOVASCULAR RISKS | VITAMIN-D SUPPLEMENTATION | BONE-MINERAL DENSITY | HORMONE REPLACEMENT THERAPY | FOR-CLINICAL-DENSITOMETRY | INTRAVENOUS ZOLEDRONIC ACID | VERTEBRAL FRACTURE RISK | ENDOCRINOLOGY & METABOLISM | X-RAY ABSORPTIOMETRY | PRIOR BISPHOSPHONATE THERAPY | ESTROGEN PLUS PROGESTIN | Osteoporosis, Postmenopausal - epidemiology | Risk Assessment - methods | Age Distribution | Osteoporosis, Postmenopausal - diagnosis | Bone Density - physiology | Humans | Middle Aged | Osteoporotic Fractures - prevention & control | Osteoporosis, Postmenopausal - complications | Bone Density Conservation Agents - therapeutic use | Europe - epidemiology | Hip Fractures - etiology | Biomarkers - blood | Drug Monitoring - methods | Hip Fractures - epidemiology | Osteoporotic Fractures - etiology | Absorptiometry, Photon | Osteoporosis, Postmenopausal - drug therapy | Medication Adherence | Hip Fractures - prevention & control | Aged, 80 and over | Female | Aged | Osteoporotic Fractures - epidemiology | Practice guidelines (Medicine) | Osteoporosis | Care and treatment | Postmenopausal women | Diagnosis | Health aspects | Position Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study
by Modi, A and Sen, S and Adachi, J.D and Adami, S and Cortet, B and Cooper, A.L and Geusens, P and Mellstrom, D and Weaver, J and van den Bergh, J.P and Nguyen, A.M and Sajjan, S and MUSIC-OS Study Grp and MUSIC-OS Study Group and Göteborgs universitet and Gothenburg University and Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition and Sahlgrenska Academy and Centre for Bone and Arthritis Research and Sahlgrenska akademin and Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
Osteoporosis International, ISSN 0937-941X, 2016, Volume 27, Issue 3, pp. 1227 - 1238
The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women... 
Postmenopausal | Health-related quality of life | Osteoporosis | Medicine & Public Health | Orthopedics | Rheumatology | Gastrointestinal | Bisphosphonates | Treatment satisfaction | Endocrinology | POPULATION | TRACT SAFETY | HEALTH PLAN | PERSISTENCE | FRACTURE RISK | ALENDRONATE | BISPHOSPHONATE THERAPY | ENDOCRINOLOGY & METABOLISM | RISEDRONATE | POSTMENOPAUSAL WOMEN | CLINICAL-PRACTICE | Health Resources - utilization | Medication Adherence - statistics & numerical data | Osteoporosis, Postmenopausal - epidemiology | Prospective Studies | Bone Density Conservation Agents - adverse effects | Gastrointestinal Diseases - epidemiology | Gastrointestinal Diseases - psychology | Humans | Middle Aged | Bone Density Conservation Agents - therapeutic use | Europe - epidemiology | Psychometrics | Osteoporosis, Postmenopausal - drug therapy | Patient Satisfaction | Canada - epidemiology | Diphosphonates - therapeutic use | Quality of Life | Female | Aged | Diphosphonates - adverse effects | Gastrointestinal Diseases - chemically induced | Osteoporosis, Postmenopausal - psychology | Care and treatment | Analysis | Phosphonates | Postmenopausal women | Diagnosis | Patient satisfaction | Digestive system | Menopause | Quality of life | Original | Endokrinologi och diabetes | Endocrinology and Diabetes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice
by Harvey, N.C and Glüer, C.C and Binkley, N and McCloskey, E.V and Brandi, M.-L and Cooper, C and Kendler, D and Lamy, O and Laslop, A and Camargos, B.M and Reginster, J.-Y and Rizzoli, R and Kanis, J.A
Bone, ISSN 8756-3282, 2015, Volume 78, pp. 216 - 224
Abstract Trabecular bone score (TBS) is a recently-developed analytical tool that performs novel grey-level texture measurements on lumbar spine dual X-ray... 
Orthopedics | Osteoporosis | Trabecular bone score (TBS) | FRAX | Bone mineral density | Epidemiology | Fragility fracture | RISK-FACTORS | MICROARCHITECTURAL TEXTURE | VERTEBRAL FRACTURE | IN-VIVO MEASUREMENT | MINERAL DENSITY BMD | LUMBAR SPINE | MEN | ENDOCRINOLOGY & METABOLISM | WHITE WOMEN | POSTMENOPAUSAL WOMEN | FINITE-ELEMENT-ANALYSIS | Femur - pathology | Humans | Middle Aged | Osteoporosis - diagnosis | Osteoporotic Fractures - diagnosis | Male | Bone and Bones - diagnostic imaging | Adult | Female | Osteoporotic Fractures - physiopathology | Osteoporosis - physiopathology | Diabetes Mellitus, Type 2 - complications | Osteoarthritis - complications | Bone Density | Osteoporosis, Postmenopausal - diagnosis | Cross-Sectional Studies | Risk Assessment | Risk Factors | Probability | Absorptiometry, Photon | Hyperparathyroidism, Primary - complications | Cushing Syndrome - complications | Bone and Bones - physiopathology | Algorithms | Fracture Healing | Osteoporosis, Postmenopausal - physiopathology | Aged | Lumbar Vertebrae - pathology | Corticosteroids | Parathyroid hormone | Osteoarthritis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Trabecular Bone Score evaluation in postmenopausal women with or without fractures
by Galich, A.M and Maffei, L and Premrou, V and Frigeri, A and Vega, E
Bone, ISSN 8756-3282, 12/2017, Volume 105, pp. 304 - 304
Postmenopausal women
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text MiR‐503 Regulates Osteoclastogenesis via Targeting RANK
by Chen, Chao and Cheng, Peng and Xie, Hui and Zhou, Hou‐De and Wu, Xian‐Ping and Liao, Er‐Yuan and Luo, Xiang‐Hang
Journal of Bone and Mineral Research, ISSN 0884-0431, 02/2014, Volume 29, Issue 2, pp. 338 - 347
MicroRNAs (miRNAs) play important roles in osteoclastogenesis and bone resorption. However, no study has investigated the role of miRNA in postmenopausal... 
OSTEOCLASTOGENESIS | RANK | RNA | micro | PBMC | OSTEOPOROSIS | microRNA | PBMCs | DIAGNOSIS | MICRORNAS | IDENTIFICATION | ESTABLISHMENT | SUSCEPTIBILITY GENES | CHINESE WOMEN | ENDOCRINOLOGY & METABOLISM | DIFFERENTIATION | MUTATIONS | EXPRESSION | Leukocytes, Mononuclear - metabolism | Osteoclasts - pathology | Osteoporosis, Postmenopausal - mortality | Humans | Middle Aged | MicroRNAs - metabolism | Osteoporosis, Postmenopausal - pathology | Osteoporosis, Postmenopausal - genetics | Osteoporosis, Postmenopausal - therapy | Stem Cells - metabolism | Osteoclasts - metabolism | Lipopolysaccharide Receptors | Cell Differentiation - genetics | Leukocytes, Mononuclear - pathology | Animals | Receptor Activator of Nuclear Factor-kappa B - biosynthesis | Receptor Activator of Nuclear Factor-kappa B - genetics | Stem Cells - pathology | Female | Mice | MicroRNAs - genetics | Osteoporosis | Postmenopausal women | MicroRNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
by Kendler, David L and Marin, Fernando and Zerbini, Cristiano A F and Russo, Luis A and Greenspan, Susan L and Zikan, Vit and Bagur, Alicia and Malouf-Sierra, Jorge and Lakatos, Péter and Fahrleitner-Pammer, Astrid and Lespessailles, Eric and Minisola, Salvatore and Body, Jean Jacques and Geusens, Piet and Möricke, Rüdiger and López-Romero, Pedro
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 230 - 240
No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with... 
ZOLEDRONIC ACID | MEDICINE, GENERAL & INTERNAL | PLACEBO | VERTEBRAL FRACTURES | DENOSUMAB | BMD | RISK | ALENDRONATE | LOW BONE MASS | Osteoporosis, Postmenopausal - epidemiology | Risedronic Acid - therapeutic use | Teriparatide - therapeutic use | Humans | Middle Aged | Osteoporotic Fractures - diagnostic imaging | Osteoporosis, Postmenopausal - complications | Osteoporotic Fractures - etiology | Incidence | Americas - epidemiology | Aged, 80 and over | Female | Osteoporotic Fractures - physiopathology | Risedronic Acid - adverse effects | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Osteoporotic Fractures - prevention & control | Bone Density Conservation Agents - therapeutic use | Europe - epidemiology | Osteoporosis, Postmenopausal - drug therapy | Radiography | Bone Density - drug effects | Osteoporosis, Postmenopausal - physiopathology | Teriparatide - adverse effects | Aged | Clinical trials | Osteoporosis | Postmenopausal women | Analysis | Menopause | Patients | Bisphosphonates | Studies | Fractures | Vitamin D | Parathyroid hormone | Risedronic acid | Womens health | Biocompatibility | Bone density | Drug therapy | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK
by Kanis, J A and McCloskey, E V and Johansson, H and Strom, O and Borgstrom, F and Oden, A and Natl Osteoporosis Guideline Grp and National Osteoporosis Guideline Group and Department of Mathematical Sciences, Mathematical Statistics and Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa and Naturvetenskapliga fakulteten and Faculty of Sciences and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Sahlgrenska akademin and Institutionen för matematiska vetenskaper, matematisk statistik and Institute of Medicine, Department of Public Health and Community Medicine
Osteoporosis International, ISSN 0937-941X, 10/2008, Volume 19, Issue 10, pp. 1395 - 1408
Assessment and intervention thresholds are developed and proposed in men aged over 50 years and postmenopausal women for the UK based on fracture probability... 
Fracture probability | FRAX | Medicine & Public Health | Gynecology | Orthopedics | Assessment thresholds | Rheumatology | BMD | Clinical risk factors | Intervention thresholds | Osteoporotic fracture | Endocrinology | FRAX (R) | COST-EFFECTIVENESS | BONE-MINERAL DENSITY | fracture probability | GLUCOCORTICOID-INDUCED OSTEOPOROSIS | ELDERLY-WOMEN | osteoporotic fracture | ALENDRONATE | intervention thresholds | POSTMENOPAUSAL OSTEOPOROSIS | ECONOMIC-EVALUATION | VERTEBRAL FRACTURE RISK | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | assessment thresholds | clinical risk factors | RISEDRONATE | Osteoporosis, Postmenopausal - epidemiology | Risk Assessment - methods | Age Factors | Humans | Middle Aged | Osteoporosis, Postmenopausal - complications | Fractures, Bone - epidemiology | Male | Osteoporosis - drug therapy | Patient Selection | Fractures, Bone - etiology | Aged, 80 and over | Female | Osteoporosis - epidemiology | Bone Density | Decision Support Techniques | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - economics | Algorithms | Cost-Benefit Analysis | Osteoporosis - complications | Femur Neck - physiopathology | Aged | United Kingdom - epidemiology | Fractures, Bone - prevention & control | Osteoporosis | Bones | Bone density | Fractures | Health risk assessment | Postmenopausal | methods | 80 and over | epidemiology | Great Britain | Endokrinologi och diabetes | Bone Density Conservation Agents | Physiology | Endocrinology and Diabetes | drug therapy | complications | Risk Assessment | Fysiologi | Femur Neck | prevention & control | etiology | economics | physiopathology | Bone | therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
by Bone, H G and Dempster, D W and Eisman, J A and Greenspan, S L and McClung, M R and Nakamura, T and Papapoulos, S and Shih, W J and Rybak-Feiglin, A and Santora, A C and Verbruggen, N and Leung, A T and Lombardi, A
Osteoporosis International, ISSN 0937-941X, 2/2015, Volume 26, Issue 2, pp. 699 - 712
Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone... 
Postmenopausal | Osteoporosis | Cathepsin K | Medicine & Public Health | Orthopedics | Rheumatology | Fracture | Odanacatib | Endocrinology | TARGET | RESORPTION | BONE-MINERAL DENSITY | DENOSUMAB | ALENDRONATE | DISCOVERY | WOMEN | ENDOCRINOLOGY & METABOLISM | CATHEPSIN-K INHIBITOR | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Humans | Osteoporotic Fractures - prevention & control | Osteoporosis, Postmenopausal - complications | Biphenyl Compounds - adverse effects | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Osteoporotic Fractures - etiology | Biphenyl Compounds - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Patient Selection | Bone Density - drug effects | Biphenyl Compounds - pharmacology | Hip Joint - physiopathology | Female | Femur Neck - physiopathology | Osteoporosis, Postmenopausal - physiopathology | Aged | Osteoporotic Fractures - physiopathology | Research Design | Cathepsin K - antagonists & inhibitors | Postmenopausal women | Research | Demographic aspects | Drug therapy | Health aspects | Enzymes | Inhibitor drugs | Fractures | Menopause | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights